What is Abeomics?
Abeomics operates at the intersection of advanced molecular biology and pharmaceutical research, specializing in the development of essential biotechnology products. The company's portfolio includes a comprehensive suite of engineered cell lines, recombinant biosimilar antibodies, and specialized assay kits designed to streamline complex research workflows. By offering bespoke services such as custom antibody development and stable cell line engineering, Abeomics serves as a vital partner for organizations focused on immunology, oncology, and infectious disease research. Their commitment to precision and innovation enables pharmaceutical entities to accelerate drug screening processes and enhance the reliability of their experimental outcomes.
How much funding has Abeomics raised?
Abeomics has raised a total of $43K across 1 funding round:
Debt
$43K
Debt (2021): $43K with participation from PPP
Key Investors in Abeomics
PPP
Public-Private Partnership
What's next for Abeomics?
With the recent infusion of capital, Abeomics is poised to enter a new phase of operational maturity. The strategic focus will likely shift toward expanding its manufacturing capacity for recombinant proteins and enhancing its proprietary drug screening platforms. As the company navigates the complexities of the life sciences sector, this investment provides the necessary runway to deepen its R&D capabilities and potentially explore new therapeutic modalities. By maintaining a rigorous focus on quality and technical excellence, Abeomics is set to capture a larger share of the global research reagents market, effectively bridging the gap between laboratory discovery and clinical application.
See full Abeomics company page
